<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39346662</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2732-494X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Antimicrobial stewardship &amp; healthcare epidemiology : ASHE</Title><ISOAbbreviation>Antimicrob Steward Healthc Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of heterologous and homologous COVID-19 vaccination among immunocompromised individuals: a systematic literature review and meta-analysis.</ArticleTitle><Pagination><StartPage>e152</StartPage><MedlinePgn>e152</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e152</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/ash.2024.369</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">We assessed the effectiveness of heterologous vaccination strategy in immunocompromised individuals regarding COVID-19 outcomes, comparing it to homologous approaches.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Systematic literature review/meta-analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We searched PubMed, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science from January 1, 2020 to September 29, 2023. We included studies that evaluated the heterologous vaccination strategy on immunocompromised individuals through outcomes related to COVID-19 (levels of anti-SARS-CoV-2 spike protein IgG, neutralizing antibodies, symptomatic COVID-19 infection, hospitalization, and death) in comparison to homologous schemes. We also used random-effect models to produce pooled odds ratio estimates. Heterogeneity was investigated with I<sup>2</sup> estimation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Eighteen studies met the inclusion criteria for this systematic review. Fourteen of them provided quantitative data for inclusion in the meta-analysis on vaccine response, being four of them also included in the vaccine effectiveness meta-analysis. The vaccination strategies (heterologous vs homologous) showed no difference in the odds of developing anti-SARS-CoV-2 spike protein IgG (odds ratio 1.12 [95% Cl: 0.73-1.72]). Heterologous schemes also showed no difference in the production of neutralizing antibodies (odds ratio 1.48 [95% Cl: 0.72-3.05]) nor vaccine effectiveness in comparison to homologous schemes (odds ratio 1.52 [95% CI: 0.66-3.53]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Alternative heterologous COVID-19 vaccinations have shown equivalent antibody response rates and vaccine effectiveness to homologous schemes, potentially aiding global disparity of vaccine distribution.</AbstractText><CopyrightInformation>© The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pardo</LastName><ForeName>Isabele</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maezato</LastName><ForeName>Aline Miho</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callado</LastName><ForeName>Gustavo Yano</ForeName><Initials>GY</Initials><Identifier Source="ORCID">0000-0001-6694-6569</Identifier><AffiliationInfo><Affiliation>Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutfreund</LastName><ForeName>Maria Celidonio</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Mariana Kim</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0001-8709-5484</Identifier><AffiliationInfo><Affiliation>Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Takaaki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4751-6859</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salinas</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases &amp; Geographic Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramanian</LastName><ForeName>Aruna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1373-6768</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases &amp; Geographic Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edmond</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0002-4144-8974</Identifier><AffiliationInfo><Affiliation>Department of Medicine, West Virginia University School of Medicine, Morgantown, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diekema</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Luiz Vicente</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Alexandre R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-7577-7688</Identifier><AffiliationInfo><Affiliation>Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antimicrob Steward Healthc Epidemiol</MedlineTA><NlmUniqueID>9918266096106676</NlmUniqueID><ISSNLinking>2732-494X</ISSNLinking></MedlineJournalInfo><CoiStatement>Authors have no commercial or financial involvement, except for AS, whose institution receives research funding from Moderna, Inc., Pfizer, Inc., and Janssen, Inc, and DJD, whose institution has research contracts and received payments for the development of antifungal susceptibility testing technology from BioMerieux, Inc., and Affinity Biosensors, Inc., and received payments for consulting regarding an investigational vaccine from ExBaq, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39346662</ArticleId><ArticleId IdType="pmc">PMC11427957</ArticleId><ArticleId IdType="doi">10.1017/ash.2024.369</ArticleId><ArticleId IdType="pii">S2732494X24003693</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020. https://www.who.int/directorgeneral/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---20-march-2020
</Citation></Reference><Reference><Citation>
Mathieu E, Ritchie H, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19), 2020. Published online at OurWorldinData.org. https://ourworldindata.org/coronavirus
</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–2615. 10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra AR, Kobayashi T, Suzuki H, et al. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis. J Infect 2022;84:297–310. 10.1016/j.jinf.2021.12.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.12.035</ArticleId><ArticleId IdType="pmc">PMC8720049</ArticleId><ArticleId IdType="pubmed">34982962</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer 2021;9:e002630. 10.1136/jitc-2021-002630</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-002630</ArticleId><ArticleId IdType="pmc">PMC8206176</ArticleId><ArticleId IdType="pubmed">34117116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair MJ, Berger JM, Berghoff AS, et al. Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations. JAMA Oncol 2022;8:106. 10.1001/jamaoncol.2021.5437</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2021.5437</ArticleId><ArticleId IdType="pmc">PMC8485209</ArticleId><ArticleId IdType="pubmed">34591965</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis 2021;72:340–350. 10.1093/cid/ciaa863</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa863</ArticleId><ArticleId IdType="pmc">PMC7337668</ArticleId><ArticleId IdType="pubmed">33501974</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. The Lancet 2022;399:924–944. 10.1016/S0140-6736(22)00152-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatar M, Shoorekchali JM, Faraji MR, Seyyedkolaee MA, Pagán JA, Wilson FA. COVID-19 vaccine inequality: a global perspective. J Glob Health 2022;12:03072. 10.7189/jogh.12.03072</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.12.03072</ArticleId><ArticleId IdType="pmc">PMC9559176</ArticleId><ArticleId IdType="pubmed">36227706</ArticleId></ArticleIdList></Reference><Reference><Citation>Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med 2022;386:1046–1057. 10.1056/NEJMoa2116414</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116414</ArticleId><ArticleId IdType="pmc">PMC8820244</ArticleId><ArticleId IdType="pubmed">35081293</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. 10.1371/journal.pmed.1000097</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF. Meta-analysis of observational studies in epidemiology a proposal for reporting. JAMA 2000;283:2008. 10.1001/jama.283.15.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.15.2008</ArticleId><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilishvili T, Fleming-Dutra KE, Farrar JL, et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel—33 U.S. Sites, January–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:753–758. 10.15585/mmwr.mm7020e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7020e2</ArticleId><ArticleId IdType="pmc">PMC8136422</ArticleId><ArticleId IdType="pubmed">34014909</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinson ML, Lapham J. Prevalence of immunosuppression among US adults. JAMA 2024;331:880–882. 10.1001/jama.2023.28019</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.28019</ArticleId><ArticleId IdType="pmc">PMC10870224</ArticleId><ArticleId IdType="pubmed">38358771</ArticleId></ArticleIdList></Reference><Reference><Citation>Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377–384. 10.1136/jech.52.6.377</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech.52.6.377</ArticleId><ArticleId IdType="pmc">PMC1756728</ArticleId><ArticleId IdType="pubmed">9764259</ArticleId></ArticleIdList></Reference><Reference><Citation>
Doebler. Meta-analysis of diagnostic accuracy with mada. R Project Organization. https://cran.r-project.org/web/packages/mada/vignettes/mada.pdf
</Citation></Reference><Reference><Citation>Sharifi Aliabadi L, Karami M, Barkhordar M, et al. Homologous versus Heterologous prime-boost COVID-19 vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial. Front Immunol 2023;14:1237916. 10.3389/fimmu.2023.1237916</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1237916</ArticleId><ArticleId IdType="pmc">PMC10427916</ArticleId><ArticleId IdType="pubmed">37593732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonelli M, Mrak D, Tobudic S, et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann Rheum Dis 2022;81:687–694. 10.1136/annrheumdis-2021-221558</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221558</ArticleId><ArticleId IdType="pubmed">35027397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A, Chiang TP, Kim JD, et al. Improved humoral immunogenicity with mRNA-1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses. Clin Transplant 2022;36:e14738. 10.1111/ctr.14738</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.14738</ArticleId><ArticleId IdType="pmc">PMC9348091</ArticleId><ArticleId IdType="pubmed">35670813</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang TP, Alejo JL, Mitchell J, et al. Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination. Am J Transplant 2022;22:2254–2260. 10.1111/ajt.17061</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.17061</ArticleId><ArticleId IdType="pmc">PMC9111240</ArticleId><ArticleId IdType="pubmed">35429211</ArticleId></ArticleIdList></Reference><Reference><Citation>Dib M, Le Corre N, Ortiz C, et al. SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: a prospective cohort study. Lancet Reg Health Am 2022;16:100371. 10.1016/j.lana.2022.100371</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100371</ArticleId><ArticleId IdType="pmc">PMC9503242</ArticleId><ArticleId IdType="pubmed">36185969</ArticleId></ArticleIdList></Reference><Reference><Citation>Erol Ç, Kuloğlu ZE, Kayaaslan B, et al. BNT162b2 or CoronaVac as the third dose against Omicron: neutralizing antibody responses among transplant recipients who had received two doses of CoronaVac. Viruses 2023;15:1534. 10.3390/v15071534</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15071534</ArticleId><ArticleId IdType="pmc">PMC10383925</ArticleId><ArticleId IdType="pubmed">37515220</ArticleId></ArticleIdList></Reference><Reference><Citation>Fendler A, Shepherd STC, Au L, et al. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell 2022;40:114–116. 10.1016/j.ccell.2021.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.12.013</ArticleId><ArticleId IdType="pmc">PMC8716090</ArticleId><ArticleId IdType="pubmed">34968417</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaete-Argel A, Saavedra-Alarcón V, Sauré D, et al. Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients. Front Immunol 2023;14:1135478. 10.3389/fimmu.2023.1135478</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1135478</ArticleId><ArticleId IdType="pmc">PMC10044136</ArticleId><ArticleId IdType="pubmed">36999018</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Sars-Cov-2 antibody levels in blood cancer patients after a third Sars-Cov-2 “Booster” vaccination: observational data from the LLS National Registry. Blood 2021;138(Supplement 1):185–185. 10.1182/blood-2021-151419</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2021-151419</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinzel A, Schrezenmeier E, Regele F, et al. Three-month follow-up of heterologous vs. homologous third SARS-CoV-2 vaccination in kidney transplant recipients: secondary analysis of a randomized controlled trial. Front Med 2022;9:936126. 10.3389/fmed.2022.936126</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.936126</ArticleId><ArticleId IdType="pmc">PMC9353321</ArticleId><ArticleId IdType="pubmed">35935786</ArticleId></ArticleIdList></Reference><Reference><Citation>Honfi D, Gémes N, Szabó E, et al. Comparison of homologous and heterologous booster SARS-CoV-2 vaccination in autoimmune rheumatic and musculoskeletal patients. Int J Mol Sci 2022;23:11411. 10.3390/ijms231911411</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911411</ArticleId><ArticleId IdType="pmc">PMC9569441</ArticleId><ArticleId IdType="pubmed">36232710</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JM, Lee J, Huh KH, et al. Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: an observational study. J Clin Virol 2023;159:105374. 10.1016/j.jcv.2022.105374</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105374</ArticleId><ArticleId IdType="pmc">PMC9800015</ArticleId><ArticleId IdType="pubmed">36592547</ArticleId></ArticleIdList></Reference><Reference><Citation>Körber N, Holzmann-Littig C, Wilkens G, et al. Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipients. Front Immunol 2023;14:1172477. 10.3389/fimmu.2023.1172477</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1172477</ArticleId><ArticleId IdType="pmc">PMC10102365</ArticleId><ArticleId IdType="pubmed">37063863</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Pestana J, Almeida Viana L, Nakamura MR, et al. Immunogenicity after a heterologous BNT262b2 versus homologous booster in kidney transplant recipients receiving 2 doses of CoronaVac vaccine: a prospective cohort study. Transplantation 2022;106:2076–2084. 10.1097/TP.0000000000004260</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004260</ArticleId><ArticleId IdType="pmc">PMC9521386</ArticleId><ArticleId IdType="pubmed">35939382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak D, Sieghart D, Simader E, et al. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nat Commun 2022;13:5362. 10.1038/s41467-022-33036-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33036-y</ArticleId><ArticleId IdType="pmc">PMC9467419</ArticleId><ArticleId IdType="pubmed">36097029</ArticleId></ArticleIdList></Reference><Reference><Citation>Narongkiatikhun P, Noppakun K, Chaiwarith R, et al. Immunogenicity and safety of homologous and heterologous prime-boost of CoronaVac® and ChAdOx1 nCoV-19 among hemodialysis patients: an observational prospective cohort study. Vaccines 2023;11:715. 10.3390/vaccines11040715</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11040715</ArticleId><ArticleId IdType="pmc">PMC10146055</ArticleId><ArticleId IdType="pubmed">37112627</ArticleId></ArticleIdList></Reference><Reference><Citation>Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, et al. Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial. JAMA Intern Med 2022;182:165. 10.1001/jamainternmed.2021.7372</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.7372</ArticleId><ArticleId IdType="pmc">PMC8689434</ArticleId><ArticleId IdType="pubmed">34928302</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EA, Ngecu W, Stoddart L, et al. Heterologous versus homologous boosting elicits qualitatively distinct, BA.5–cross-reactive T cells in transplant recipients. JCI Insight 2023;8:e168470. 10.1172/jci.insight.168470</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.168470</ArticleId><ArticleId IdType="pmc">PMC10322695</ArticleId><ArticleId IdType="pubmed">37104041</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Ciesla AA, Mak J, et al. Early estimates of updated 2023–2024 (Monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults—increasing community access to testing program, United States, September 2023–January 2024. MMWR Morb Mortal Wkly Rep 2024;73:77–83. 10.15585/mmwr.mm7304a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7304a2</ArticleId><ArticleId IdType="pmc">PMC10843065</ArticleId><ArticleId IdType="pubmed">38300853</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO. Executive Summary. https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3
</Citation></Reference><Reference><Citation>Truong TT, Ryutov A, Pandey U, et al. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series. EBioMedicine 2021;67:103355. 10.1016/j.ebiom.2021.103355</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103355</ArticleId><ArticleId IdType="pmc">PMC8072072</ArticleId><ArticleId IdType="pubmed">33915337</ArticleId></ArticleIdList></Reference><Reference><Citation>Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome Coronavirus 2 replication in an immunocompromised patient. J Infect Dis 2021;223:23–27. 10.1093/infdis/jiaa666</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa666</ArticleId><ArticleId IdType="pmc">PMC7797758</ArticleId><ArticleId IdType="pubmed">33089317</ArticleId></ArticleIdList></Reference><Reference><Citation>
FAQs for the Interim Clinical Considerations for COVID-19 Vaccination. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/faq.html
</Citation></Reference><Reference><Citation>Yamey G, Garcia P, Hassan F, et al. It is not too late to achieve global COVID-19 vaccine equity. BMJ 2022;376:e070650. 10.1136/bmj-2022-070650</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-070650</ArticleId><ArticleId IdType="pmc">PMC8943596</ArticleId><ArticleId IdType="pubmed">35331982</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox AM, Choi Y, Lin L. Substantial disparities in COVID-19 vaccine uptake and unmet immunization demand in low- and middle-income countries: study examines COVID-19 vaccine uptake and unmet immunization demand in low- and middle-income countries. Health Aff 2023;42:1697–1705. 10.1377/hlthaff.2023.00729</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2023.00729</ArticleId><ArticleId IdType="pubmed">38048509</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>